VJHemOnc Podcast
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
Jun 3, 2024
Hematologist Naveen Pemmaraju discusses BPDCN treatment, focusing on CD123-targeting agents like Tagraxofusp. The guests emphasize the importance of early diagnosis, CNS involvement, and tailored strategies for treating adolescents and young adults with this aggressive disease.
34:39
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- CD123-targeting agents like Tagraxofusp show promise in BPDCN treatment.
- Young BPDCN patients require tailored approaches due to distinct disease biology.
Deep dives
CD123 Targeting in Treatment of BPDCN
The use of CD123 targeting agents like Tagraxofusp in treating BPDCN has shown significant promise, leading to high response rates in refractory patients. The CD123 antigen plays a vital role in BPDCN diagnosis and targeted therapy. Clinical trials with these agents have demonstrated efficacy, with high response rates and improved survival outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
